Maria Alejandra

[Maria Alejandra @AlejaMolina]

@GehlawatM Very proud 🥹

[Meenal Gehlawat, MD @GehlawatM]

I am thrilled to share that I won 1st Prize at the ACP 2026 Poster Competition for our study on opioid disparities! 🏆

#ACP2026 #MedicalResearch #DVH

[Jun Gong, MD @jgong15]

Including readership in Asia @AsiaBioSpectrum @BioSpectrum

https://t.co/RDNTyE1t4U

@DaniCastilloMD @ronanhsieh

[Dani Castillo @DaniCastilloMD]

Happy to share our original publication https://t.co/Ly3YyuxBMr
@montypal @jgong15 @ronanhsieh @DanengLi @OncoAlert @gagan_brar24 @SteveMaronMD @GastroRes @StoCANcer

[Meenal Gehlawat, MD @GehlawatM]

Presenting our latest work at SOHO 2026!

[HopeForStomachCancer @StoCANcer]

Today we want to take a moment to recognize the people who show up for this community every single day. Caregivers. Volunteers. Advocates. Healthcare professionals who go the extra mile. We see it, and we're grateful for it. 💜

[Dani Castillo @DaniCastilloMD]

It’s honored to be part of this amazing community.@cityofhope @CityofHopeSurg @MOASC_Office @gagan_brar24

[Dani Castillo @DaniCastilloMD]

Listening to expert real world experiences with dual blockage in MSI-H mCRC.

[Dani Castillo @DaniCastilloMD]

Volrustomig in MSS CRC.

[Dani Castillo @DaniCastilloMD]

Learning how to polish grant proposals from sharp minds has been an amazing experience,connecting with so many dedicated physician-scientists in the world of cancer research.#AACR @christine_lovly @BReinfeld @UCSD @oncodaily

[Paulo G Bergerot @PauloBergerot]

Kicking off #ISEO26 #ExerciseOncology Inaugural Conf. #Hiedelberg
Kudos to the organizers-very happy to collaborate
@exoncolgermany @fitaftercancer @SteindorfKaren @annemariamay @ProfRobNewton @KarenWonders @DrBetofMDPhD @KerryCourneya #karenMustian #DanielGalvao @urspecial2

[Dani Castillo @DaniCastilloMD]

It’s an amazing opportunity to meet GI oncology colleagues, we exchange experiences and insights, with the goal to make the community better and more opportunities for our patients. Thank you for the invitations. @_backtableONC @Kate_Baker_MD @jgong15 @cityofhope @CedarsSinai @ronanhsieh

[Gagan Brar @gagan_brar24]

⭐️Immunotherapy plus chemotherapy in advanced biliary tract cancers: pros and cons: Expert Review
Written with the invaluable and truly remarkable Dr Valle (and help from biorender) @curecc @DanengLi @montypal @DaniCastilloMD @cityofhope
https://t.co/BJPSwROHe0

[Dani Castillo @DaniCastilloMD]

Periscope II should not be interpreted as evidence that regional therapy has no role in GCPM. It demostrates CRS+ HIPEC did not improve OS without biomarker guided systemic tx alone in unselected population with PCI < 7, diff from piano study, next step should focus on IO and Taget tx ( more effective systemic tx) and translational endpoints that should will benefit.@oncodaily @OncoAlert @COH_SurgOnc @jgong15 @ronanhsieh @Yanghee61217641 @laleh_melstrom

[Duaa Kanan, MD @duaakanan21]

July marks a special time as we welcome the new class of resident and fellow physicians ✨

Around this time last year, I was navigating the transition as a new fellow. Excited to share my reflections and lessons learned! @ASCO #ASCOconnection

https://t.co/odzpS0pHjg

[OncoDaily @oncodaily]

@DanengLi @cityofhope @COHMedOnc @myESMO @gagan_brar24 @DaniCastilloMD We would like to inform you that your post has been published on OncoDaily. Thank you for sharing!
https://t.co/zKDjLw26jL

[Claude @claudeai]

Introducing Claude Science, a new app designed with every stage of research in mind.

Artifacts traced to their code, environments managed on demand, and 60+ optional scientific databases that you can connect.

Available now in beta.

[Sumanta K. Pal, MD, FASCO @montypal]

In light of some of the exciting news for CAR-T for solid tumors, posting out @cityofhope podcast featuring Christine Brown, PhD, who leads a tremendous program that has developed over 2 decades in this very space. Do have a listen! https://t.co/cJuUgnnRTA

[Dana-Farber @DanaFarber]

A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer.

In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy.

While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers.

As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.”

Congratulations to the researchers and patients who made this important progress possible. 👏👏👏

Video Courtesy: @asco

[Dani Castillo @DaniCastilloMD]

It’s a pleasure to meet with medical oncologists to exchange experiences and insights from our MDT discussions on improving patient outcomes,delighted to be a co-panelist alongside Dr. Bryan, the Chief Medical Officer from IQVIA.